Join the 'Cholesterol' group to help and get support from people like you.
Posted 26 Dec 2012 by Drugs.com
December 26, 2012 – On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments. HoFH is a rare inherited condition that makes the body unable to remove LDL cholesterol, often called the “bad” cholesterol, from the blood, causing abnormally high levels of circulating LDL cholesterol. In the United States, HoFH occurs in approximately one in one million individuals. For those with HoFH, heart attacks and death often occur before age 30. Juxtapid works by impairing the creation of the lipid particles that ultimately give rise to LDL. Juxtapid is a capsule tak ... Read more
Related support groups: High Cholesterol, Cholesterol, High Cholesterol - Familial Homozygous, Hypercholesterolemia, Familial Homozygous, Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous